LASERTEAM
Medical laser technology

The Future of

Skin rejuvenation laser treatment

Revolutionary versatile technology,
Ultra small spots,
Narrowest ablative micro-tunnels,
Wide coagulation,
Low pain, Low downtime,
Safe, All skin types.

5 major issues with current lasers

1

OVERSATURATED

Me too options

2

OVERSPECIALIZED

Specialized lasers for each problem

- Wrinkles
- Scars
- Pigmentation-reducing
- Cost-effectiveness

5 major issues with current lasers

3

MULTIPLE SIDE EFFECTS

Side Effects

- Scarring
- Burns
- Pain
- Infection
- Hypopigmentation
- PIH (Post Inflammatory Hyperpigmentation)

5 major issues with current lasers

4

BARRIERS FOR
PEOPLE OF COLOR

50%

of potential patients of color
can't receive best treatment

5 major issues with current lasers

5

LONG DOWNTIME -
UP TO 2 WEEKS!

Epicare novel technology

Specifications

Property	
Wavelength	1940 nm
Average Power	1.8 W
Pulse Duration	12 ns
Pulse Energy	1.8 mJ
Peak Power	150 KW
Repetition Rate	1 KHz
Laser Spot size	40 µm

Low power / High efficacy aspect

Small footprint

No need for water cooling

Outshines the competition

Max results. Min discomfort. Min downtime.

Laser Machine	Epicare	Er-Yag	CO2
Coagulation BETTER +	Hemostasis to 300% Controlled while lase	From 0+ to <<30%	30%
Spot size SMALLER +	40µm Downtime less than 4 days	170µm	120µm
Max power	2 Watt	10Watt	60Watt

Fotona SP Dynamis
2,940 nm Er:YAG

Fraxel re:store
1550 nm
Erbium

Short downtime

Controlled Coagulation

UltraPulse,
10,600 nm
CO2

Short downtime

Our vision: All-in-One

One platform for multiple indications with minimal downtime and maximum patient comfort

Indication:

- Wrinkles
- Rejuvenation
- Pigmentation
- Acne Scarring
- Tightening
- Scars
- All skin types

Introducing

Epicare's Breakthrough Technology

One Laser. Endless Solutions.

LASERTEAM

- Many fast and high-power laser pulses
- On the same spot.
- With or without peripheral thermal effect



The ability to achieve a wider coagulation density, while performing less epidermis damage

---

CO2 Technologies

Long Pulse

Epicare treatment modes
Mode “Coagulative”

The Epicare’s coagulative mode creates **narrow ablation micro-tunnels** (black arrow) surrounded by **wide coagulation zones** (Orange Zone). At the **15% maximum density** (based on ~350 µm coagulation width), the ablation portion is **under 1.5%**, giving an ablation-to-coagulation ratio of ~0.1.
This mode is **less painful**, **less bleeding**, and the **epidermis closes within 24 hours.**
Unlike conventional non-ablative lasers, the coagulation is produced by **uniform depth heating** (not tied to the absorption curve), and heat **does not extend much beyond the coagulated tissue**.

Epicare treatment modes
Mode “Ablative”

The Epicare’s ablative mode creates **narrow ablation micro-tunnels** (black arrow) with **narrow surrounding coagulation** (Orange Zone). At the **8% maximum density** (based on ~150 µm coagulation width), the ablation area is **~3.5%**, giving an ablation-to-coagulation ratio of **~0.8**.
The **microtunnels are much narrower** than CO_2 lasers, with a **similar ablation/coagulation ratio**.



Histological comparison

Actual Coagulation width

80 mJ 120 mJ 160 mJ



High coagulation microcolumns at various energies

300% coagulation

Ultra Narrow Spots

LASERTEAM



CO2 Technologies



A side-by-side comparison between our low-frequency operation and the CO2RE ablation with the same scale

Proven efficacy in published studies

Lasers in Surgery and Medicine

PRECLINICAL STUDY OPEN ACCESS

Evaluation of a Novel Ablative 1940 nm Pulsed Laser for Skin Rejuvenation

Yoav Gronovich[1] | Yaniv Raderman[1] | Ronen Toledano[1] | Rotem Nahear[2] | Neria Suliman[2] | Alon Shacham[2] | David Fridman[2] | Salman Noach[2,5]

[1]Plastic and Reconstructive Surgery Department, Shaare Zedek Me... of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel | [5]Laser Team Medical Ltd, Jerusalem, Israel | [6]Department ... Faculty, Jerusalem College of Technology, Jerusalem, Israel

Correspondence: Yoav Gronovich (yoavgg@gmail.com)

Received: 18 February 2024 | **Revised:** 29 May 2024 | **Accept...**

Keywords: 1940 nm | ablative | laser | resurfacing | skin rejuven...

PRECLINICAL STUDY OPEN ACCESS

Safety Assessment of a 1940 nm Tm:YAP Laser for Fractional Skin Ablation in a Swine Model

Yuval Ramot[1,2] | Michal Steiner[3] | Udi Vazana[4] | Rotem Nahear[5] | Neria Suliman[5] | David J. Friedman[5] | Salman Noach[5,6] | Abraham Nyska[7]

[1]Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel | [2]The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel | [3]Preclinical Consultant, Rehovot, Israel | [4]LAHAV CRO, Kibbutz Lahav, Israel | [5]Laser Team Medical Ltd., Jerusalem, Israel | [6]Department of Applied Physics, Electro-Optics Engineering Faculty, Jerusalem College of Technology, Jerusalem, Israel | [7]Consultant in Toxicologic Pathology, Tel Aviv University, Tel Aviv, Israel

Correspondence: Abraham Nyska (anyska@nyska.net)

Received: 23 February 2025 | **Revised:** 11 April 2025 | **Accepted:** 18 April 2025

Funding: The study was funded by LaserTeam Ltd., Jerusalem, Israel and supported by the Israel Innovation Authority (Grant No. 73276).

Keywords: 1940 nm laser | collagen remodeling | dermatologic applications | epidermal regeneration | fractional laser ablation | histopathology | laser safety and efficacy | skin resurfacing | swine model | thulium-doped yttrium aluminum perovskite (Tm:YAP)

Top cited article WILEY 2025

Granted Patents

2µm Q-SWITCH Technology

Enable to achieve high energy pulses in nanosecond regime

Status: **GRANTED**
Filing date: April 2, 2018

Granted US Patent No. 10,978,850

1.7 to 3µm Tunable Q-Switch Technology

Enable to achieve different wavelengths of high energy pulses in nanosecond regime with a tunable spectral range of at least 20 nm;

Status: **GRANTED**
Filing date: May 22, 2019

Granted US Patent No. 11,791,602

Pending Patents

Precise control over laser medical treatments

Enable to achieve Different controlled depth and different controlled coagulation width on a human tissue (skin)

Status: **PENDING -** National phase
(US; China; European patent office; Korea)

Filing date: Aug 29, 2023

Pending PCT Application No. PCT/IL2023/050915

Special laser pulse scanning to achieve fast treatment

Enable to achieve ultra fast treatment on treated area

Status: **PENDING PCT**

Filing date: Jan 25, 2024

Pending PCT Application No. PCT/IL2024/050100

Future applications and markets

Gynecology

Vaginal rejuvenation and more

Ophthalmology

ENT

Middle ear surgery, stapedotomy

Laryngeal cancer, and more

Brain Surgery

Drug Delivery

Enhanced trans dermal drug delivery

Enhanced Transdermal Delivery of Sumatriptan Using Laser Technology

Experiment done by Prof. Amnon Sintov Ben-Gurion U, April 2024



Methodology

Diffusion Cell System: Used excised porcine ear skin.
Laser Treatment: Applied as pretreatment for transdermal delivery.
Control: Compared laser-treated vs. untreated skin.

Key Results

Increased Permeability

Laser-treated Skin: 252 µg/cm² after 6 hours (x42)
Untreated Skin: 6 µg/cm² after 6 hours.
Statistical Significance: ANOVA, $p << 0.05$.

Conclusion

LTM's treatment significantly enhances skin permeability for sumatriptan, indicating its potential for better drug absorption.

Company history



Roadmap (9/24 – 9/27)

Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q1 2027 | Q3 2027

Q4 | 2025

Design freeze

Design input documents,
GUI,
Industrial Design,
Mechanic,
Electronics and **software** development
Protocol & Helsinki

Q1-Q2 | 2026

Pivotal Study

Periorbital wrinkles
50 total patients
2 treatments
Follow-up:
3 months
GLP testing
Preparation for submission

Q3 | 2026

FDA Submission

510K
Periorbital wrinkles

Q1 | 2027

FDA clearance

510K
Periorbital wrinkles

KOL Evaluation
5 sites

Transfer-to-Production

Starting Sales,

Business development

Regulatory pathway to market success

Executed by Hogan Lovells US LLP and BioVision Ltd.

510(k) submission

Q3 2026

Estimated time for the submission date

Q1 2027

Estimated time to receive FDA clearance

Pre-Submission meeting, to obtain the FDA's early feedback on the proposed regulatory strategy:

1. **Indications for Use:** The Epicare System is indicated for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue for the treatment of wrinkles.
2. **Predicate and Reference devices:**
   - Primary Predicate: LASEMD Laser System (K171009)
   - Reference Device: Syneron Medical Ltd. CO2RE (K151655)
3. **GLP Animal Study:** evaluation of the Safety and Efficacy of the Epicare System in Performing Fractional Skin Ablation in a Swine Model
4. **Clinical Study:** A Prospective, Interventional, Study for the Assessment of the Safety and Efficacy of Epicare for the Treatment of Periorbital Wrinkles

MARKET SUMMARY

Reflecting newest trends, consumer behavior, and energy-device market shifts

- Skin rejuvenation with fast, visible results and **minimal downtime** is now the #1 unmet need, especially among Millennials.
- Demand for **ongoing anti-aging treatments** continues to rise, driven by **preventive care** and earlier adoption.
- Existing technologies still have major limitations, especially for Asian, Hispanic, Middle Eastern, and darker skin tones, increasing demand for **safer alternatives**.
- Premium rejuvenation devices continue to command the highest physician fees, and the market is willing to **pay more for superior outcomes**.
- Demand for **full-body rejuvenation** is rising, including hands, neck, chest, and off-face pigmentation.
- Clinics are aggressively replacing older CO_2 systems, **seeking technologies that offer CO_2-level outcomes with dramatically lower downtime** and lower PIH risk.

Raising $10M (2026 – 2028)

Marketing & regulations (5 M)

Regulatory submissions (1M): CE, CFDA

NEW indication, Clinical trials and Regulatory submissions (total: 2M):

Tightening, Rejuvenation, Pigmentation, Acne Scarring, Scars, for all skin types

PR campaigns (0.5M)

Build stock, Sales & Distribution force and KOL's **(1.5M)**

R&D + Engineering (2 M)

Next generation product:

Articulated Arm transition to fiber **(0.5M)**

Higher energy laser development **(0.5M)**

Cost reduction project (1M)

Decrease BOM from

New Articulated Arm

Injection molds for plastic parts and sand casting

Dedicated electronics and firmware

G&A + IP (3M)

IP worldwide (0.5M)

G&A for 3 years (2.5M)

Our team is a collection of engineers and medical doctors who understand the market and its needs

CEO

Pini Ben Elazar, MBA

Veteran CEO in healthcare, led Mor Research applications, TTO of Clalit for 20 years.

Founded more than 80 startup companies.

CTO & CO-Founder

Prof. Salman Noach

Veteran CTO with 25 years of experience, inventor and founder of the 2µm solid-state laser lab at JCT, a faculty member at the physics department at JCT.

CMO

Dr. David J. Friedman, MD.

Expert in non-surgical aesthetic and laser dermatology, with extensive experience in clinical trials and training.

US Board Certified Dermatologist in the US and Israel. Former Assistant Professor at Brown. Medical Director of Candela Israel and Physician Trainer at Allergan Israel.

COO

Avi Mendelson, B.SC

Over 25 years of senior management in R&D and operations within startup and leading Medical Device companies (Lumenis, Candela)

Scientific advisory board

Dr. Jeffrey S. Dover, MD

A former Associate Professor of Dermatology at Harvard Medical School, he is the author of over 550 scientific publications and has co-authored and edited over 55 textbooks. Dr. Dover is the past president of the American Society for Lasers in Medicine and Surgery, the American Society for Dermatologic Surgery, and the New England Dermatology Society.

Dr. Sarit Cohen, MD

Head of the Israeli Center of Facial Sculpting, specializes in invasive and minimally invasive facial aesthetic procedures. Board-certified in plastic, reconstructive, and aesthetic surgery, she is a consultant for leading aesthetic companies and has published extensively on facial and body procedures.

Paul M. Friedman, MD

Director of Dermatology & Laser Surgery Center in Houston. Board-certified in dermatology, he trained at NYU and completed a fellowship in dermatologic and Mohs surgery. He is recognized globally for his advancements in dermatologic laser treatments.

Dr. Yakir Levin, MD, PhD

An Assistant Professor of Dermatology at Harvard Medical School and is a physician-scientist at the Massachusetts General Hospital. He maintains an active clinical practice at MGH's acclaimed Laser and Cosmetic Center and a significant research portfolio at its world-renowned Wellman Center for Photomedicine. He subspecializes in aesthetic dermatology and in the treatment of disfiguring birthmarks in children and conducts human and preclinical research studies geared toward improving these treatments

Invest in Epicare

The game-changing innovation the laser market has been waiting for!

Thank You!

pinib@lasertm.com

LASERTEAM
Medical laser technology